ARCT-021

BIOLOGICAL2 trials

Sponsors

Arcturus Therapeutics, Inc.

Conditions

COVID-19Corona Virus InfectionSARS-CoV-2SARS-CoV-2 Infection

Phase 1

A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults

CompletedNCT05037097

Arcturus Therapeutics, Inc.Corona Virus Infection, COVID-19, SARS-CoV-2 Infection

Start: 2021-08-30End: 2023-12-19Updated: 2025-10-15

Phase 2

Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021

TerminatedNCT04728347

Arcturus Therapeutics, Inc.SARS-CoV-2

Start: 2021-01-04End: 2021-12-28Updated: 2024-12-30

Related Papers

Vaccination of non-human primates with self-amplifying mRNA vaccines reveal two distinct immunotypes across major SARS-CoV-2 variants.

The Journal of Immunology2022-05-01